


Claims

1. A compound of formula (I);



wherein:

Y is phenyl, unsubstituted or substituted with one, two or three substituents;

R¹ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstituted C₁₋₆ alkyl;


R² is (CH₂)_mR³ where m is 0 or 1;

or R¹ and R² together with N to which they are attached form an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl ring;

R³ is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl group, an unsubstituted or substituted C₃₋₈ cycloalkyl group, an unsubstituted or substituted straight or branched C₁₋₁₀ alkyl, an unsubstituted or substituted C₅₋₇ cycloalkenyl or R⁵;

R⁴ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstituted C₁₋₆ alkyl, COCH₃, or SO₂Me;

R⁵ is



wherein p is 0, 1 or 2, and X is CH₂, O, S, SO or SO₂;

R⁶ is C₃₋₆cycloalkyl or 4- to 7- membered non aromatic heterocyclic group, and R¹⁰ is hydrogen or R¹⁰ is C₃₋₆cycloalkyl or 4- to 7- membered non aromatic heterocyclic group, and R⁶ is hydrogen;

R⁷ is OH, C₁₋₆alkoxy, NR^{8a}R^{8b}, NHCOR⁹, NHSO₂R⁹, SOqR⁹;

R^{8a} is H or C₁₋₆alkyl;

R^{8b} is H or C₁₋₆alkyl;


R⁹ is C₁₋₆alkyl;

q is 0, 1 or 2;

or a pharmaceutically acceptable derivative thereof.

2. A compound as claimed in claim 1 wherein X is CH₂, O or S.

3. A compound as claimed in claim 1 wherein compounds of formula (I) are compounds of formula (Ia):



wherein:

R^3 is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl group;

R^6 is C_{3-6} cycloalkyl;

5 R^{11} is selected from halo, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy;
 d is 0, 1, 2 or 3;

and pharmaceutically acceptable derivatives thereof.

4. A compound as claimed in any one of claims 1 to 3 wherein R^6 is either cyclopentyl or
 10 cyclopropyl and R^{10} is hydrogen.
5. A compound as claimed in claims 1 or 2 wherein R^{10} is cyclopropyl and R^6 is hydrogen.
6. A compound as claimed in any preceding claim selected from Examples 1 to 153.
7. A pharmaceutical composition comprising a compound as claimed in claims 1 to 6 or a
 15 pharmaceutically acceptable derivative thereof and a pharmaceutical carrier or diluent thereof.
8. A pharmaceutical composition as claimed in claim 7 further comprising a second
 20 therapeutic agent.
9. A method of treating a human or animal subject suffering from a condition which is
 mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject
 a therapeutically effective amount of a compound of formula (I) or (Ia) as claimed in claims 1 to 6
 25 or a pharmaceutically acceptable derivative thereof.
10. A method of treating a human or animal subject suffering from an immune disorder, an
 inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or
 osteoporosis which method comprises administering to said subject an effective amount of a
 30 compound of formula (I) or (Ia) as claimed in claims 1 to 6 or a pharmaceutically acceptable
 derivative thereof.